Jazz Pharmaceuticals JAZZ Acquisition accounting inventory fair value step-up adjustment
Acquisition accounting inventory fair value step-up adjustment at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:InventoryStepUpValueAdjustment.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's acquisition accounting inventory fair value step-up adjustment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's acquisition accounting inventory fair value step-up adjustment?
- Jazz Pharmaceuticals (JAZZ) reported acquisition accounting inventory fair value step-up adjustment of $37.5M in Q1 2026.
- How has Jazz Pharmaceuticals's acquisition accounting inventory fair value step-up adjustment changed year-over-year?
- Jazz Pharmaceuticals's acquisition accounting inventory fair value step-up adjustment increased by 25.4% year-over-year, from $29.9M to $37.5M.
- What does acquisition accounting inventory fair value step-up adjustment mean?
- The extra cost recognized when selling inventory acquired through a business purchase.
- How do you interpret acquisition accounting inventory fair value step-up adjustment?
- High values indicate recent acquisition activity; as this expense rolls off, it typically leads to improved gross margins in future periods.
- How does acquisition accounting inventory fair value step-up adjustment compare across companies?
- Commonly seen in the periods immediately following M&A activity in the pharmaceutical and manufacturing sectors.